« Back

Research & Clinical Trials

Allergy & Immunology Research & Clinical Trials banner: a man working in a lab looking at a slide.S

Since the Division's inception in the early 1970s, it has been one of the premier research-oriented allergy centers in the nation. It has contributed many novel concepts in allergy and immunology and consistently published high-impact research articles in superior journals such as:

  • Journal of Experimental Medicine
  • Journal of Clinical Investigation
  • Nature Immunology
  • Journal of Immunology
  • New England Journal of Medicine
  • Transplantation
  • PLOS One
doctor with patient
 

Every year since its inception, members of the Allergy Division have had funding from NIH for research conducted in the division. In addition, many members have served in prestigious NIH study sections to evaluate research and education in the field of allergy and immunology.

Some of the pioneering concepts and research activities are:

  • Identification of CC chemokines
    as IgE-independent
    histamine-releasing factors
  • The use of CpG for treatment
    for Th2 inflammation
    and asthma
  • Identification of pollen NADPH
    oxidase as a critical player
    in allergic airway
    inflammation
  • Identification of mitochondrial
    proteins and their role
    in allergic inflammation
  • Bronchscopy & BAL studies in
    patients with allergic asthma
    subjects for biomarkers
  • Examination of relationship
    between food allergy and
    respiratory allergy
  • Defining the role of
    xenoestrogens in asthma
    and other allergic disorders

Available Resources

UTMB Health is home to several unique facilities and programs that support clinical research and provide world class clinical and research opportunities.

NIH NHLBI Proteomics Center
UTMB is one of seven institutions which are part of a new proteomics program launched by the NHLBI on August 15, 2010. Collectively, the participating centers were awarded $83.5 million. UTMB has been a part of the NHLBI Proteomics Initiative since 2002. The new network consists of Boston University, Johns Hopkins University, Massachusetts General Hospital, Stanford University, the University of California-Los Angeles, the University of Texas Health Sciences Center at San Antonio, and UTMB Health.

Institute for Translational Sciences
The ITS is the academic home of a five-year, $21.5 million Clinical Translational Sciences Award (CTSA) by the National Institutes of Health– National Center for Research Resources. The National CTSA Consortium, which currently includes 46 institutions, is working to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research.

Clinical Research Center

Child Health Research Center

Research Pharmacy

Aerospace Medicine Program

Affiliation with Shriners Burns Hospital

WHO Collaborating Center for Tropical Diseases

Research & Clinical Trials

Research is a central focus of UTMB's Division of Allergy and Immunology. Since the creation of the division in the early 1970s, it has been one of the region's premier research-oriented allergy centers. Our research focuses on advancing the understanding of allergic and immunologic disorders, as well as improving measures for diagnosis and treatment. Clinical trials are carried out under strict guidelines with great attention to participant safety.

doctor ata work station
Clinical studies

Individuals choose to participate in clinical research for many reasons. Some like the idea of being able to receive treatment with promising therapies before they are approved by the Food and Drug Administration for widespread commercial use. Others have tried conventional treatments and are in search of a new option. Still others may participate in clinical research in efforts to advance science and medicine.

We currently are conducting studies on hereditary angioedema, asthma, and immunodeficiencies. New studies are added frequently; call to check with us about our latest research and trials.

For more information about research studies and clinical trials, please contact Dr. Rana Bonds or Dr. Andrew Grant at 409.772.2436.

The Division of Allergy & Immunology at UTMB provides state-of-the-art care for over 2,300 patients with various allergic and immunologic disorders per year. A major factor in the division's ability to provide the latest treatments is their participation in clinical trials of both therapeutics and diagnostics. These include:

  1. Dyax; Ascending four dose placebo controlled study to assess the efficacy and tolerability of DX-88(recombinant plasma kallikrein inhibitor)administered following onset of acute attacks of hereditary angioedema. Successor study: An open label study to assess the efficacy and tolerability of repeated doses of DX-88 (recombinant plasma kallikrein inhibitor) in patients with hereditary angioedema.
  2. LevPharma; Clinical study to investigate the efficacy and safety of purified C1 esterase inhibitor (human) for the treatment of hereditary angioedema (HAE) in acute attacks and as prophylactic treatment to prevent HAE attacks.
  3. Jerini AG; Randomized, double-blind, placebo-controlled, multicenter study of a subcutaneous formulation of Icatibant for the treatment of hereditary angioedema.
  4. Pharming; A randomized, placebo-controlled, double-blind Phase II study of the safety and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema.
  5. ZLB Behring; Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial hereditary angioedema (HAE) attacks.
  6. Baxter: Tolerability and pharmacokinetic comparison of immune globulin intravenous (human) administered intravenously or subcutaneously in subjects with primary immunodeficiency diseases.
  7. Shire; A phase III randomized double-blind, placebo-controlled multicenter study of icatibant for subcutaneous injection in patients with acute attacks of hereditary angioedema (HAE).
  8. Baxter; Efficacy, tolerability and pharmacokinetic comparison of immune globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) administered intravenously or subcutaneously following administration of recombinant human hyaluronidase (rHuPH20) in subjects with primary immunodeficiency diseases.
  9. BOBCAT study on markers of airway inflammation in severe asthma. This study was performed in collaboration with a national consortium of universities working closely with Genentech to identify molecular biomarkers of severe asthma.
  10. Studies of the human response to inhaled and ingested allergens; Perimenstrual asthma.
female doctor smiling
 

Placing a study at UTMB is a simple phone call or email away. By contacting the Division, an investigator can be identified and copies of CVs and licenses obtained.

For more information contact:
Rana Bonds, MD
Phone: 409.772.2436
Fax: 409.772.9532
Email: rsbonds@utmb.edu

The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.

Currently available protocols are:
  • CAP - Community Acquired Pneumonia Orderset
  • Congestive Heart Failure (CHF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Ketoacidosis Adult, ICU
  • General Medicine Admission
  • Immunodeficiency Flow Panel
  • MICU/CCU Admission Order Set
  • Oral Analgesic Medicaitons
  • Parenteral Opioids
  • Sepsis, Adult ICU

All protocols can be found in the EPIC order set section.

» For more information

Meaning Use logo

The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.

Site Managed by UTMB Information Design Services.